RT Journal Article SR Electronic T1 HIV status alters disease severity and immune cell responses in β variant SARS-CoV-2 infection wave JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.11.23.20236828 DO 10.1101/2020.11.23.20236828 A1 Karim, Farina A1 Gazy, Inbal A1 Cele, Sandile A1 Zungu, Yenzekile A1 Krause, Robert A1 Bernstein, Mallory A1 Ganga, Yashica A1 Rodel, Hylton A1 Mthabela, Ntombifuthi A1 Mazibuko, Matilda A1 Khan, Khadija A1 Muema, Daniel A1 Ramjit, Dirhona A1 Ndung’u, Thumbi A1 Hanekom, Willem A1 Gosnell, Bernadett I. A1 , A1 Lessells, Richard A1 Wong, Emily A1 de Oliveira, Tulio A1 Moosa, Mahomed-Yunus S. A1 Lustig, Gila A1 Leslie, Alasdair A1 Kløverpris, Henrik A1 Sigal, Alex YR 2021 UL http://medrxiv.org/content/early/2021/09/05/2020.11.23.20236828.abstract AB There are conflicting reports on the effects of HIV on COVID-19. Here we analyzed disease severity and immune cell changes during and after SARS-CoV-2 infection in 236 participants from South Africa, of which 39% were people living with HIV (PLWH), during the first and second (β dominated) infection waves. The second wave had more PLWH requiring supplemental oxygen relative to HIV negative participants. Higher disease severity was associated with low CD4 T cell counts and higher neutrophil to lymphocyte ratios (NLR). Yet, CD4 counts recovered and NLR stabilized after SARS-CoV-2 clearance in wave 2 infected PLWH, arguing for an interaction between SARS-CoV-2 and HIV infection leading to low CD4 and high NLR. The first infection wave, where severity in HIV negative and PLWH was similar, still showed some HIV modulation of SARS-CoV-2 immune responses. Therefore, HIV infection can synergize with the SARS-CoV-2 variant to change COVID-19 outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Bill and Melinda Gates Investment INV-018944 to Alex Sigal. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the University of KwaZulu-Natal Institutional Review Board (approval BREC/00001275/2020). Written informed consent was obtained for all enrolled participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll de-identified data is included or available upon request.